| Detailed information |
|---|
| CancerLivER ID | 2581 |
| Biomarker | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxin-related transmembrane protein, Cathepsin D, Ras |
| Biomarker Name/Symbol (given in Publication) | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxinâ€related transmembrane protein, Cathepsin D, Ras homolog gene family member A, Cytochrome c oxidase subunit IV isoform 1, CD74 antigen, Benzodiazapine receptor, Nitrogen fixation cluster-like, Calcium/calmodulin-dependent protein kinase II gamma, Cytochrome b-245 alpha polypeptide, Major histocompatibility complex class I A, Major histocompatibility complex class I F, Major histocompatibility complex class II DP beta 1, Actin related protein 2/3 complex subunit 2, Ribosomal protein S19, Catenin (cadherinâ€associated protein) alpha 1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in L1 than L0 (with Fisher ratio more than 8.9) |
| Level of significance | P = 0.001 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | induces apoptosis of some types of cancer cells, and IGFBP4 acts as an inhibitor of IGF-in- duced cell proliferation. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |